Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys

Virology

Volumn 367, Issue 2, 2007, Pages 390-397

  Someya, Kenji ^a,b   Xin, Ke Qin ^b   Ami, Yasushi ^a   Izumi, Yasuyuki ^a   Mizuguchi, Hiroyuki ^c   Ohta, Shinrai ^a,b   Yamamoto, Naoki ^a   Honda, Mitsuo ^a   Okuda, Kenji ^b  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Cellular immunity; DNA vaccine; Pathogenic SHIV challenge; Recombinant Ad5 35

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; DNA VACCINE; PLASMID DNA; RECOMBINANT DNA;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG MEGADOSE; ENVELOPE GENE; GROUP SPECIFIC ANTIGEN GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; MONKEY; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS GENE; VIRUS LOAD; VIRUS RECOMBINANT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD4 LYMPHOCYTE COUNT; DISEASE MODELS, ANIMAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE PRODUCTS, GAG; GENETIC VECTORS; HAPLORHINI; HUMANS; RNA, VIRAL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 5; HUMAN IMMUNODEFICIENCY VIRUS 1; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34848914469     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.06.012     Document Type: Article

References (40)

1. Abbink P., Lemckert A.A., Ewald B.A., Lynch D.M., Denholtz M., Smits S., Holterman L., Damen I., Vogels R., Thorner A.R., O'Brien K.L., Carville A., Mansfield K.G., Goudsmit J., Havenga M.J., and Barouch D.H. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81 (2007) 4654-4663
2. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., McClure H.M., McNicholl J.M., Moss B., and Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74
3. Ami Y., Izumi Y., Matsuo K., Someya K., Kanekiyo M., Horibata S., Yoshino N., Sakai K., Shinohara K., Yamazaki S., Yamamoto N., and Honda M. Prime-boost vaccination with recombinant Mycobacterium bovis Bacillus Calmette Guérin and a non-replicating vaccinia virus recombinant leads to long-lasting and effective immunity. J. Virol. 79 (2005) 12871-12879
4. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., Truitt D.M., Sumida S.M., Kishko M.G., Arthur J.C., Korioth-Schmitz B., Newberg M.H., Gorgone D.A., Lifton M.A., Panicali D.L., Nabel G.J., Letvin N.L., and Goudsmit J. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 15 (2004) 6290-6297
5. Barratt-Boyes S.M., Soloff A.C., Gao W., Nwanegbo E., Liu X., Rajakumar P.A., Brown K.N., Robbins P.D., Murphey-Corb M., Day R.D., and Gambotto A. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors. J. Gen. Virol. 87 Pt. 1 (2006) 139-149
6. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., Tang A., Chen M., Huang L., Harris V., Freed D.C., Wilson K.A., Dubey S., Zhu D.M., Nawrocki D., Mach H., Troutman R., Isopi L., Williams D., Hurni W., Xu Z., Smith J.G., Wang S., Liu X., Guan L., Long R., Trigona W., Heidecker G.J., Perry H.C., Persaud N., Toner T.J., Su Q., Liang X., Youil R., Chastain M., Bett A.J., Volkin D.B., Emini E.A., and Shiver J.W. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77 (2003) 6305-6313
7. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., Gu L., Martin J.E., Novik L., Chakrabarti B.K., Butman B.T., Gall J.G.D., Richter King C., Andrews C.A., Sheets R., Gomez P.L., Mascola J.R., Nabel G.J., Graham B.S., and the Vaccine Research Center 006 Study Team. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 194 (2006) 1638-1649
8. De Jong J.C., Wermenbol A.G., Verweij-Uijterwaal M.W., Slaterus K.W., Wertheim-Van Dillen P., Van Doornum G.J., Khoo S.H., and Hierholzer J.C. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J. Clin. Microbiol. 37 (1997) 3940-3945
9. Eda Y., Murakami T., Ami Y., Nakasone T., Takizawa M., Someya K., Kaizu M., Izumi Y., Yoshino N., Matsushita S., Higuchi H., Matsui H., Shinohara K., Takeuchi H., Koyanagi Y., Yamamoto N., and Honda M. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J. Virol. 80 (2006) 5563-5570
10. Gaggar A., Shayakhmetov D.M., and Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9 (2003) 1408-1412
11. Imler J.L. Adenovirus vectors as recombinant viral vaccines. Vaccine 13 (1995) 1143-1151
12. Kostense S., Koudstaal W., Sprangers M., Weverling G.J., Penders G., Helmus N., Vogels R., Bakker M., Berkhout B., Havenga M., and Goudsmit J. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18 (2004) 1213-1216
13. Lemckert A.A., Sumida S.M., Holterman L., Vogels R., Truitt D.M., Lynch D.M., Nanda A., Ewald B.A., Gorgone D.A., Lifton M.A., Goudsmit J., Havenga M.J., and Barouch D.H. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol. 79 (2005) 9694-9701
14. Letvin N.L., Barouch D.H., and Montefiori D.C. Prospect for vaccine protection against HIV-1 Infection and AIDS. Annu. Rev. Immunol. 20 (2002) 73-99
15. Lu Y., Salvato M.S., Pauza C.D., Li J., Sodroski J., Manson K., Wyand M., Letvin N., Jenkins S., Touzjian N., Chutkowski C., Kushner N., LeFaile M., Payne L.G., and Roberts B. Utility of SHIV for testing HIV-1 vaccine candidates in macaques. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 12 (1996) 99-106
16. Marttila M., Persson D., Gustafsson D., Kathryn Liszewski M.K., John P., Atkinson J.P., Wadell G., and Niklas Arnberg N. CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J. Virol. 79 (2005) 14429-14436
17. Mascola J.R. Defining the protective antibody response for HIV-1. Curr. Mol. Med. 3 (2003) 209-216
18. Mascola J.R., Sambor A., Beaudry K., Santra S., Welcher B., Louder M.K., Vancott T.C., Huang Y., Chakrabarti B.K., Kong W.P., Yang Z.Y., Xu L., Montefiori D.C., Nabel G.J., and Letvin N.L. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J. Virol. 79 (2005) 771-779
19. Mellors J.W., Rinaldo C.R.Jr., Gupta P., White R.M., Todd J.A., and Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272 (1996) 1167-1170
20. + lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126 (1997) 946-954
21. Mizuguchi H., and Hayakawa T. Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 285 (2002) 69-77
22. Mothe B.R., Horton H., Carter D.K., Allen T.M., Liebl M.E., Skinner P., Vogel T.U., Fuenger S., Vielhuber K., Rehrauer W., Wilson N., Franchini G., Altman J.D., Haase A., Picker L.J., Allison D.B., and Watkins D.I. Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J. Virol. 76 (2002) 875-884
23. Musey L., Hughes J., Schacker T., Shea T., Corey L., and McElrath M.L. Cytotoxic T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med. 30 (1997) 1267-1274
24. Ophorst O.J., Kostense S., Goudsmit J., De Swart R.L., Verhaagh S., Zakhartchouk A., Van Meijer M., Sprangers M., Van Amerongen G., Yuksel S., Osterhaus A.D., and Havenga M.J. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine 22 (2004) 3035-3044
25. Patke D.S., Langan S.J., Carruth L.M., Keating S.M., Sabundayo B.P., Margolick J.B., Quinn T.C., and Bollinger R.C. Association of Gag-specific T lymphocyte responses during the early phase of human immunodeficiency virus type 1 infection and lower virus load set point. J. Infect. Dis. 186 (2002) 1177-1180
26. Rea D., Havenga M.J., van Den Assem M., Sutmuller R.P., Lemckert A., Hoeben R.C., Bout A., Melief C.J., and Offringa R. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 166 (2001) 5236-5244
27. Reimann K.A., Li J.T., Voss G., Lekutis C., Tenner-Racz K., Racz P., Lin W., Montefiori D.C., Lee-Parritz D.E., Lu Y., Collman R.G., Sodroski J., and Letvin N.L. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J. Virol. 70 (1996) 3198-3206
28. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., Liu J., Thorner A.R., Swanson P.E., Gorgone D.A., Lifton M.A., Lemckert A.A., Holterman L., Chen B., Dilraj A., Carville A., Mansfield K.G., Goudsmit J., and Barouch D.H. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441 (2006) 239-243
29. + T lymphocytes in macaques by infection with a pathogenic simian/human immunodeficiency virus. Clin. Exp. Immunol. 122 (2002) 381-389
30. Segerman A., Mei Y.F., and Wadell G. Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines. J. Virol. 74 (2000) 1457-1467
31. Shayakhmetov D.M., Papayannopoulou T., Stamatoyannopoulos G., and Lieber A. Efficient gene transfer into human CD34 (+) cells by a retargeted adenovirus vector. J. Virol. 74 (2000) 2567-2583
32. Shinohara K., Sakai K., Ando S., Ami Y., Yoshino N., Takahashi E., Someya K., Suzaki Y., Nakasone T., Sasaki Y., Kaizu M., Lu Y., and Honda M. A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkeys. J. Gen. Virol. 80 Pt. 5 (1998) 1231-1240
33. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., Zhang Z.Q., Simon A.J., Trigona W.L., Dubey S.A., Huang L., Harris V.A., Long R.S., Liang X., Handt L., Schleif W.A., Zhu L., Freed D.C., Persaud N.V., Guan L., Punt K.S., Tang A., Chen M., Wilson K.A., Collins K.B., Heidecker G.J., Fernandez V.R., Perry H.C., Joyce J.G., Grimm K.M., Cook J.C., Keller P.M., Kresock D.S., Mach H., Troutman R.D., Isopi L.A., Williams D.M., Xu Z., Bohannon K.E., Volkin D.B., Montefiori D.C., Miura A., Krivulka G.R., Lifton M.A., Kuroda M.J., Schmitz J.E., Letvin N.L., Caulfield M.J., Bett A.J., Youil R., Kaslow D.C., and Emini E.A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 (2002) 331-335
34. Someya K., Xin K.Q., Matsuo K., Okuda K., Yamamoto N., and Honda M. A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity. J. Virol. 78 (2004) 9842-9853
35. Someya K., Cecilia D., Ami Y., Nakasone T., Matsuo K., Burda S., Yamamoto H., Yoshino N., Kaizu M., Ando S., Okuda K., Zolla-Pazner S., Yamazaki S., Yamamoto N., and Honda M. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. J. Virol. 79 (2005) 1452-1462
36. Someya K., Ami Y., Nakasone T., Izumi Y., Matsuo K., Horibata S., Xin K.Q., Yamamoto H., Okuda K., Yamamoto N., and Honda M. Induction of effective cellular and humoral immune responses by a prime-boost vaccine encoded with simian immunodeficiency virus gag/pol. J. Immunol. 176 (2006) 1784-1795
37. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Bethune M.P., Kostense S., Penders G., Helmus N., Koudstaal W., Cecchini M., Wetterwald A., Sprangers M., Lemckert A., Ophorst O., Koel B., van Meerendonk M., Quax P., Panitti L., Grimbergen J., Bout A., Goudsmit J., and Havenga M. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77 (2003) 8263-8271
38. Xin K.Q., Jounai N., Someya K., Honma K., Mizuguchi H., Naganawa S., Kitamura K., Hayakawa T., Saha S., Takeshita F., Okuda K., Honda M., Klinman D.M., and Okuda K. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther. 12 (2005) 1769-1777
39. Xin K.Q., Sekimoto Y., Takahashi T., Mizuguchi H., Ichino M., Yoshida A., and Okuda K. Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV. Vaccine 25 (2007) 3809-3815
40. Yoshino N., Ami Y., Terao K., Tashiro F., and Honda M. Upgrading of flow cytometric analysis for absolute counts, cytokines and other antigenic molecules of cynomolgus monkeys (Macaca fascicularis) by using anti-human cross-reactive antibodies. Exp. Anim. 49 (2000) 97-110